Curriculum Vitase 15/02/2016
Evangelos Briasoulis MD, PhD
Associate Professor of Oncology
Durrent affiliations
Head of Academic Department of Clinical Hematology
Scientic Director of Cancer Bioban Center, interscience Molecular Lab
University of Ioannina
Address:
University of Ioannina
TT Pedinis 434
Ioannina, GR 45500
Tel : +30651093202, +302651007713
Fax : +30651094477
Email: ebriasou@otenet.gr, ebriasou@me.com
Web: http://www.uoi.gr/services/lab-net/units_en.html
http://www.uoi.gr/services/lab-net/net-web/Cancer_Biobank_en.pdf
Personal information
Merital status:
Married, two children
Place and date of birth: Trikala, Greece 27/Jan/1953
Current research activities and interests
Dr. Evangelos Briasoulis (Professor) is Head of the Cancer Biobank Center (which is a member of the
European Biobanking and Biomolecular Resources Research Infrastructure), the interscience Molecular
Oncology Lab and Director of Academic Department of Hematology, University of Ioannina. He has as a
strong research background and expertise in experimental therapeutics, early development of anticancer
drugs, in studying natural bioactive compounds and in screening and clinically managing hereditary cancer
predisposition. The The iMOL, which he leads, is a fully equipped lab that routinely works in banking
human genetic material and human cell cultures, and currently focuses its research on screening natural
compounds for biologic activity and toxicity, and on discovering novel specific cancer targets and
microRNA biomarkers.
1/9
2/15/2016
Education- Professional carrier
1971-1975
School of Theology, Univercity of Athens
1976-1982
Medical School, University of Athens
1982-1984
Public Health service
1984-1989
Internal Medicine. Senior House Officer, Ist Public General Hospital of the National Insurance
Institution, Athens
1989
Board certified in Internal Medicine
1989-1990
Head in Internal Medicine, Public Health Center, Aliartos Viotias
1990-1993
Senior Registrar in Medical Oncology, Ioannina University Hospital
1993
Board certified in Medical Oncology, European Society of Medical Oncology [ESMO]
1993-1994
Medical Oncologist, Ioannina University Hospital
1994-1995
Clinical Research Fellow, Phase I Unit, Centre for Cancer Therapeutics, ICR and Royal Marsden
Horpital, London
1996-2002
Senior Medical Oncologist, Head of the Phase I Unit, Ioannina University Horpital
2002-2008
Assistant Professor of Oncology, Medical Scholl, Uninersity of Ioannina
2008- cont
Associate Professor of Oncology, Medical Scholl, Uninersity of Ioannina
2006- cont.
ESMO Faculty member
Member in Scientific Societies and Organisations






Europen Society of Medical Oncology
American Society of Clinical Oncology
American Association for the Advancement of Science
Association of Medical Oncologists of Hellas (Board)
British Association for Cancer Rresearch
European Association for Cancer Research
2
2/15/2016






American Association for Cancer Research
Hellenic Co-operative Oncology Group
European Organisation for the Research and Treatment of Cancer, Early Clinical Studies Group.
The American Society for Biochemistry and Molecular Biology
American Chemical Society
Society for Translational Oncology
Publications
Pubmed publications: 128
Total Impact Factor: 2085
H factor: 26
Pubmed publicasions of the last 10 years
1.
Sainis I, Fokas D, Vareli K, Tzakos AG, Kounnis V, Briasoulis E: Cyanobacterial cyclopeptides as
lead compounds to novel targeted cancer drugs. Mar Drugs 2010, 8(3):629-657.
2.
Pavlidis N, Briasoulis E, Pentheroudakis G: Cancers of unknown primary site: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21 Suppl 5:v228-231.
3.
Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, Bafaloukos
D, Kosmidis P, Murray S: All about KRAS for clinical oncology practice: Gene profile, clinical implications
and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 2010.
4.
Katsanos K, Briasoulis E, Tsekeris P, Batistatou A, Bai M, Tolis C, Capizzello A, Panelos I,
Karavasilis V, Christodoulou D et al: Randomized phase II exploratory study of prophylactic amifostine in
cancer patients who receive radical radiotherapy to the pelvis. J Exp Clin Cancer Res 2010, 29(1):68.
5.
Froudarakis ME, Briasoulis E: Advanced non-small cell lung cancer: on relapse rechallenge the
tumor, not the patient. BMC Res Notes 2010, 3(1):195.
6.
Chira P, Vareli K, Sainis I, Papandreou C, Briasoulis E: Alterations of MicroRNAs in Solid Cancers
and Their Prognostic Value. Cancers 2010, 2(2):1328-1353.
7.
Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G: Phase I trial of
weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic
Cooperative Oncology Group Study. Anticancer Drugs 2010, 21(8):785-789.
8.
Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos
HP, Kosmidis P, Timotheadou E, Makatsoris T et al: A randomized phase II study of carboplatin plus
pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer
patients: a Hellenic Cooperative Oncology Group study. BMC Med 2010, 8(1):3.
9.
Καρδαμάκης Δ, Βασιλείου Β, Σπυροπούλου Δ, Μπριασούλης Ε: Η θεση της ακτινοθεραπείας στην
αντιμετώπιση ασθενών με ανεγχείρητο καρκίνο παγκρέατος. Μέρος Β: Συνδυασμένη Ακτινο-Χημειο
Θεραπεία. ΒΚΟ 2009, 8(46-54).
10.
Vareli K, Pilidis G, Mavrogiorgou MC, Briasoulis E, Sainis I: Molecular characterization of
cyanobacterial diversity and yearly fluctuations of Microcystin loads in a suburban Mediterranean Lake
(Lake Pamvotis, Greece). J Environ Monit 2009, 11(8):1506-1512.
11.
Vareli K, Briasoulis E, Pilidis G, Sainis I: Molecular confirmation of Planktothrix rubescens as the
cause of intense, microcystin—Synthesizing cyanobacterial bloom in Lake Ziros, Greece. Harmful Algae
2009, 8(3):447-453.
12.
Pectasides D, Papaxoinis G, Fountzilas G, Aravantinos G, Bamias A, Pavlidis N, Kalofonos HP,
Timotheadou E, Samantas E, Briasoulis E et al: Epithelial ovarian cancer in Greece: a retrospective study of
3
2/15/2016
1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Res 2009, 29(2):745751.
13.
Goulas V, Exarchou V, Troganis AN, Psomiadou E, Fotsis T, Briasoulis E, Gerothanassis IP:
Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells.
Mol Nutr Food Res 2009, 53(5):600-608.
14.
Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos
D, Kalogera-Fountzila A, Samantas E et al: A randomized phase III study comparing three anthracyclinefree taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative
Oncology Group study. Breast Cancer Res Treat 2009, 115(1):87-99.
15.
Christodoulou C, Kostopoulos I, Kalofonos HP, Lianos E, Bobos M, Briasoulis E, Gogas H, Razis E,
Skarlos DV, Fountzilas G: Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with
Metastatic Breast Cancer. Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with
Biomarker Evaluation. Oncology 2009, 76(4):275-285.
16.
Briasoulis E, Pavlidis N, Felip E: Cancers of unknown primary site: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20 Suppl 4:154-155.
17.
Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N: Doseranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res
2009, 15(20):6454-6461.
18.
Briasoulis E, Kardamakis D: The dawn of Clinical Oncology education in Greece. J BUON 2009,
14(2):327-332.
19.
Sainis I, Vareli K, Karavasilis V, Briasoulis E: PPARgamma: The Portrait of a Target Ally to Cancer
Chemopreventive Agents. PPAR Res 2008, 2008:436489.
20.
Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, Samantas E, Xanthakis
I, Bobos M, Galanidi E et al: Potential value of PTEN in predicting cetuximab response in colorectal cancer:
an exploratory study. BMC Cancer 2008, 8:234.
21.
Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras
A, Karina M, Xiros N, Samantas E et al: Docetaxel and carboplatin combination chemotherapy as outpatient
palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group
phase II study. Acta Oncol 2008:1-8.
22.
Pappas P, Biziota I, Marselos M, Brasoulis E: Evaluation of antiproliferative and molecular effects
of vinorelbine and its active metabolite 4-O-deacetyl-vinorelbine on human endothelial cells in an in vitro
simulation model of metronomic chemotherapy. European Journal of Cancer 2008, 6(9s):138-139.
23.
Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D,
Gogas H, Christodoulou C, Aravantinos G et al: Evaluation of the prognostic and predictive value of HER
family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group
(HeCOG) study. Br J Cancer 2008, 99(11):1775-1785.
24.
Koutras AK, Fountzilas G, Dafni U, Dimopoulos MA, Pectasides D, Klouvas G, Papakostas P,
Kosmidis P, Samantas E, Gogas H et al: Myelotoxicity as a prognostic factor in patients with advanced
breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the
Hellenic Cooperative Oncology Group. Anticancer Res 2008, 28(5B):2913-2920.
25.
Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas
E, Bafaloukos D, Stathopoulos GP et al: Postoperative dose-dense sequential chemotherapy with epirubicin,
paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative
Oncology Group randomized phase III trial HE 10/00. Ann Oncol 2008, 19(5):853-860.
26.
Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos
D, Kalogera-Fountzila A, Samantas E et al: A randomized phase III study comparing three anthracyclinefree taxane-based regimens, as first line chemotherapy, in metastatic breast cancer : A Hellenic Cooperative
Oncology Group study. Breast Cancer Res Treat 2008.
27.
Briasoulis E, Ziogas D, Fatouros M: Prophylactic surgery in the complex decision-making
management of BRCA mutation carriers. Ann Surg Oncol 2008, 15(6):1788-1790; author reply 1791-1782.
28.
Briasoulis E, Roukos DH: Contralateral prophylactic mastectomy: mind the genetics. J Clin Oncol
2008, 26(11):1909-1910; author reply 1910.
29.
Briasoulis E, Pavlidis N, Felip E: Cancers of unknown primary site: ESMO clinical recommendation
for diagnosis, treatment and follow-up. Ann Oncol 2008, 19 Suppl 2:ii106-107.
4
2/15/2016
30.
Briasoulis E, Kamposioras K, Tzovaras V, Pafitanis G, Kostoula A, Mavridis A, Pavlidis N: CENPB specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the
literature. Lung Cancer 2008, 60(2):302-306.
31.
Briasoulis E, Fountzilas G, Bamias A, Dimopoulos MA, Xiros N, Aravantinos G, Samantas E,
Kalofonos H, Makatsoris T, Mylonakis N et al: Multicenter phase-II trial of irinotecan plus oxaliplatin
[IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative
oncology group study. Cancer Chemother Pharmacol 2008, 62(2):277-284.
32.
Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV,
Economopoulos T, Kosmidis PA, Stathopoulos GP et al: Carboplatin and Paclitaxel versus Cisplatin,
Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic
Cooperative Oncology Group (HeCOG) study. Eur J Cancer 2008.
33.
Apessos A, Papadopoulou E, Belogianni I, Baratsis S, Triantafillidis JK, Kosmidis P, Karydas E,
Briasoulis E, Pisiotis C, Papazisis K et al: Inherited cancer predisposition syndromes in Greece. Anticancer
Res 2008, 28(2B):1341-1347.
34.
Tzaida O, Gogas H, Dafni U, Kyroudi A, Papaspyrou I, Kyriakou V, Malamou-Mitsi V, Alamani M,
Skopa C, Kostopoulos I et al: Evaluation of the prognostic and predictive value of HER-1/EGFR in breast
cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Oncology 2007, 72(5-6):388-396.
35.
Roukos DH, Murray S, Briasoulis E: Molecular genetic tools shape a roadmap towards a more
accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007, 6(3):308312.
36.
Roukos DH, Briasoulis E: Individualized preventive and therapeutic management of hereditary
breast ovarian cancer syndrome. Nat Clin Pract Oncol 2007, 4(10):578-590.
37.
Pentheroudakis G, Briasoulis E, Pavlidis N: Cancer of unknown primary site: missing primary or
missing biology? Oncologist 2007, 12(4):418-425.
38.
Pectasides D, Samantas E, Fountzilas G, Briasoulis E, Kosmidis P, Skarlos D, Dimopoulos MA,
Kalofonos HP, Economopoulos T, Syrigos K: Combination chemotherapy with cisplatin, etoposide and
irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative
Oncology Group. Lung Cancer 2007, 58(3):355-361.
39.
Pectasides D, Fountzilas G, Aravantinos G, Bamias A, Kalofonos HP, Skarlos D, Briasoulis E,
Konstantara A, Economopoulos T, Dimopoulos MA: Epithelial ovarian carcinoma in younger vs older
women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int
J Gynecol Cancer 2007, 17(5):1003-1010.
40.
Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki
M, Stathopoulos E, Mavroudis D et al: 'Classical' but not 'other' mutations of EGFR kinase domain are
associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer
2007, 97(11):1560-1566.
41.
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E,
Martoni A, Sorio R et al: Population pharmacokinetics and pharmacodynamics of doxorubicin and
cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet
2007, 46(12):1051-1068.
42.
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E,
Martoni A, Sorio R et al: Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin
in ovarian cancer patients: a study by the European organization for research and treatment of cancerpharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007,
13(21):6410-6418.
43.
Briasoulis E, Pavlidis N: Cancers of unknown primary site: ESMO clinical recommendations for
diagnosis, treatment and follow-up. Ann Oncol 2007, 18 Suppl 2:ii81-82.
44.
Briasoulis E, Fatouros M, Roukos DH: Level I evidence in support of perioperative chemotherapy
for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007, 14(10):2691-2695.
45.
Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis
N, Agnantis NJ: Clinicopathological study of metallothionein immunohistochemical expression, in benign,
borderline and malignant ovarian epithelial tumors. Histol Histopathol 2006, 21(4):341-347.
5
2/15/2016
46.
Pakos EE, Tsekeris PG, Pitouli EJ, Gritzeli SP, Briasoulis E: Radical versus postoperative
radiotherapy for localized prostate cancer: a 10-year experience of an academic hospital. World J Urol 2006,
24(2):214-219.
47.
Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Pavlidis N: Clinicopathologic
study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34
in patients with stage III ovarian carcinoma. Int J Gynecol Cancer 2006, 16 Suppl 1:241-246.
48.
Christodoulou C, Kalofonos HP, Briasoulis E, Bafaloukos D, Makatsoris T, Koutras A, Skarlos DV,
Samantas E: Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase
II study of the hellenic cooperative oncology group (HeCOG). Cancer Chemother Pharmacol 2006,
57(2):207-212.
49.
Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM: Selecting a
specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert
Rev Anticancer Ther 2006, 6(6):931-939.
50.
Briasoulis E, Karavasilis V, Tzamakou E, Piperidou C, Soulti K, Pavlidis N: Feasibility study and
pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. Anticancer
Drugs 2006, 17(10):1219-1222.
51.
Bai M, Katsanos KH, Economou M, Kamina S, Balli C, Briasoulis E, Kappas AM, Agnantis N,
Tsianos EV: Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case
report and review of the literature. Scand J Gastroenterol 2006, 41(7):866-869.
52.
Razis E, Skarlos D, Briasoulis E, Dimopoulos M, Fountzilas G, Lambropoulos S, Rigatos S,
Kopterides P, Efstathiou H, Tzamakou E et al: Treatment of non-small cell lung cancer with gefitinib
('Iressa', ZD1839): the Greek experience with a compassionate-use program. Anticancer Drugs 2005,
16(2):191-198.
53.
Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N:
Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with
advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. Chemotherapy
2005, 51(2-3):154-161.
54.
Pentheroudakis G, Briasoulis E, Karavassilis V, Fountzilas G, Xeros N, Samelis G, Samantas E,
Pavlidis N: Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active,
but how effective? Acta Oncol 2005, 44(2):155-160.
55.
Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D,
Skarlos D, Briasoulis E, Economopoulos T et al: Advanced stage mucinous epithelial ovarian cancer: the
Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005, 97(2):436-441.
56.
Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M: Pharmacokinetics of imatinib
mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol 2005, 56(4):358-360.
57.
Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G,
Fotsis T, Pavlidis N: Angiogenesis in cancer of unknown primary: clinicopathological study of CD34,
VEGF and TSP-1. BMC Cancer 2005, 5:25.
58.
Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G,
Fotsis T, Pavlidis N: Matrix metalloproteinases in carcinoma of unknown primary. Cancer 2005,
104(10):2282-2287.
59.
Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C,
Markopoulos C, Polychronis A, Kalofonos HP et al: Postoperative dose-dense sequential chemotherapy with
epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a
randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005,
16(11):1762-1771.
60.
Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C,
Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H et al: Paclitaxel and carboplatin as first-line
chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study
conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 2005, 92(1):1-9.
61.
Danielides V, Milionis HJ, Karavasilis V, Briasoulis E, Elisaf MS: Syndrome of inappropriate
antidiuretic hormone secretion due to recurrent oral cancer. B-ENT 2005, 1(3):151-153.
6
2/15/2016
62.
Briasoulis E, Tolis C, Bergh J, Pavlidis N: ESMO Minimum Clinical Recommendations for
diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2005, 16 Suppl
1:i75-76.
63.
Briasoulis E, Samantas E, Kalofonos H, Skarlos D, Makatsoris T, Christodoulou C, Fountzilas G,
Bamias A, Dimopoulos MA, Kosmidis P et al: Phase I study of etoposide, cisplatin and irinotecan triplet in
patients with advanced-stage small-cell lung cancer. Cancer Chemother Pharmacol 2005, 56(5):521-528.
64.
Briasoulis E, Rontogianni D, Karavasilis V, Pavlidis N: Oxaliplatin (Eloxatin) plus irinotecan
combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma. Thyroid 2005,
15(6):614-617.
65.
Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E,
Efstathiou E, Polyzos A, Fountzilas G et al: Temozolomide and cisplatin versus temozolomide in patients
with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann
Oncol 2005, 16(6):950-957.
66.
Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis B, Agnantis
NJ: CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium.
Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. Anticancer
Res 2004, 24(3a):1665-1670.
67.
Tsanou E, Ioachim E, Briasoulis E, Damala K, Charchanti A, Karavasilis V, Pavlidis N, Agnantis
NJ: Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive
breast carcinoma. Histol Histopathol 2004, 19(3):807-813.
68.
Tsanou E, Ioachim E, Briasoulis E, Charchanti A, Damala K, Karavasilis V, Pavlidis N, Agnantis
NJ: Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation
with extracellular matrix components. J Exp Clin Cancer Res 2004, 23(4):641-650.
69.
Stefanou D, Batistatou A, Briasoulis E, Arkoumani E, Agnantis NJ: Estrogen receptor beta (ERbeta)
expression in breast carcinomas is not correlated with estrogen receptor alpha (ERalpha) and prognosis: the
Greek experience. Eur J Gynaecol Oncol 2004, 25(4):457-461.
70.
Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, Damala K, Vassou A, Vartholomatos G, Kolaitis
N, Pavlidis N: The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colonystimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast
carcinoma receiving adjuvant chemotherapy. Cancer 2004, 101(8):1767-1775.
71.
Papadimitriou CA, Fountzilas G, Aravantinos G, Kalofonos C, Moulopoulos LA, Briassoulis E, Gika
D, Dimopoulos MA: Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated,
platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol Oncol
2004, 92(1):152-159.
72.
Gogas H, Bafaloukos D, Aravantinos G, Fountzilas G, Tsoutsos D, Panagiotou P, Frangia K,
Kalofonos HP, Briasoulis E, Castana O et al: Vinorelbine in combination with interleukin-2 as second-line
treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology
Group. Cancer Invest 2004, 22(6):832-839.
73.
Giaccone G, Smit EF, de Jonge M, Dansin E, Briasoulis E, Ardizzoni A, Douillard JY, Spaeth D,
Lacombe D, Baron B et al: Glufosfamide administered by 1-hour infusion as a second-line treatment for
advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur J
Cancer 2004, 40(5):667-672.
74.
Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, KalogeraFountzila A, Gogas H, Aravantinos G, Moulopoulos LA et al: Paclitaxel and epirubicin versus paclitaxel and
carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted
by the Hellenic Cooperative Oncology Group. Ann Oncol 2004, 15(10):1517-1526.
75.
Briasoulis E, Pentheroudakis G, Timotheadou H, Rammou D, Pavlidis N, Fountzilas G: Biweekly
administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.
Anticancer Drugs 2004, 15(8):747-752.
76.
Briasoulis E, Pentheroudakis G, Karavasilis V, Tzamakou E, Rammou D, Pavlidis N: Weekly
paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding
and pharmacokinetic study in patients with advanced solid tumors. Ann Oncol 2004, 15(10):1566-1573.
7
2/15/2016
77.
Briasoulis E, Karavasilis V, Tzamakou E, Rammou D, Soulti K, Piperidou C, Pavlidis N: Interaction
pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or
docetaxel. Cancer Chemother Pharmacol 2004, 53(5):452-457.
78.
Briasoulis E, Karavasilis V, Kostadima L, Ignatiadis M, Fountzilas G, Pavlidis N: Metastatic breast
carcinoma confined to bone: portrait of a clinical entity. Cancer 2004, 101(7):1524-1528.
79.
Bafaloukos D, Tsoutsos D, Fountzilas G, Linardou H, Christodoulou C, Kalofonos HP, Briassoulis
E, Panagiotou P, Hatzichristou H, Gogas H: The effect of temozolomide-based chemotherapy in patients
with cerebral metastases from melanoma. Melanoma Res 2004, 14(4):289-294.
80.
Roukos DH, Briasoulis E, Michos KM, Elisaf M, Agnantis NJ, Kappas AM: Breast and gastric
cancer: comparing what we learn. Ann Surg Oncol 2003, 10(1):92-94.
81.
Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer
of an unknown primary. Eur J Cancer 2003, 39(14):1990-2005.
82.
Pakos EE, Tsekeris PG, Briasoulis E: Recurrent prostate cancer: the role of salvage postoperative
external radiotherapy in low risk patients. J BUON 2003, 8(4):371-375.
83.
Karavasilis V, Briasoulis E, Siarabi O, Pavlidis N: Biweekly administration of low-dose docetaxel in
hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy. Clin Prostate Cancer 2003,
2(1):46-49.
84.
Ioachim E, Tsanou E, Briasoulis E, Batsis C, Karavasilis V, Charchanti A, Pavlidis N, Agnantis NJ:
Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary
invasive breast cancer. Breast 2003, 12(2):111-119.
85.
Briasoulis E, Tzouvara E, Tsiara S, Vartholomatos G, Tsekeris P, Bourantas K: Biphenotypic acute
leukemia following intensive adjuvant chemotherapy for breast cancer: case report and review of the
literature. Breast J 2003, 9(3):241-245.
86.
Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Schoffski P, Raoul JL, Hess D, Selvais R,
Lacombe D et al: Glufosfamide administered using a 1-hour infusion given as first-line treatment for
advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer
2003, 39(16):2334-2340.
87.
Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ,
Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin,
collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and
progression. Eur J Cancer 2002, 38(18):2362-2370.
88.
Briasoulis E, Karavasilis V, Tzamakou E, Haidou C, Piperidou C, Pavlidis N: Pharmacodynamics of
non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a doseescalation study. Anticancer Drugs 2002, 13(5):481-489.
89.
Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, Kalofonos C,
Skarlos D, Karabelis A, Kosmidis P: Temozolomide in combination with docetaxel in patients with
advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002,
20(2):420-425.
90.
Bafaloukos D, Aravantinos G, Fountzilas G, Stathopoulos G, Gogas H, Samonis G, Briasoulis E,
Mylonakis N, Skarlos DV, Kosmidis P: Docetaxel in combination with dacarbazine in patients with
advanced melanoma. Oncology 2002, 63(4):333-337.
91.
Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D,
Tsiakopoulos E, Kosmidis P, Tsavdaridis D et al: Randomized comparison of early versus late
hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung
cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol
2001, 12(9):1231-1238.
92.
Razis E, Dimopoulos AM, Bafaloukos D, Papadimitriou C, Kalogera-Fountzila A, Kalofonos H,
Briassoulis E, Samantas E, Keramopoulos A, Pavlidis N et al: Dose-dense sequential chemotherapy with
epirubicin and paclitaxel in advanced breast cancer. Cancer Invest 2001, 19(2):137-144.
93.
Pectasides D, Dimopoulos MA, Aravantinos G, Kalophonos HP, Papacostas P, Briasoulis E, Cogas
E, Papadimitriou C, Skarlos D, Kosmidis P et al: First line combination chemotherapy with docetaxel and
vinorelbine in advanced breast cancer. A phase II study. Anticancer Res 2001, 21(5):3575-3580.
8
2/15/2016
94.
Mavrodontidis A, Zalavras C, Skopelitou A, Karavasilis V, Briasoulis E: Leiomyosarcoma as a
second metachronous malignant neoplasm following colon adenocarcinoma. A case report and review of the
literature. Sarcoma 2001, 5(1):31-33.
95.
Froudarakis ME, Tiffet O, Fournel P, Briasoulis E, Karavasilis V, Cuilleret J, Vergnon JM: Invasive
thymoma: a clinical study of 23 cases. Respiration 2001, 68(4):376-381.
96.
Fountzilas G, Papadimitriou C, Dafni U, Bafaloukos D, Skarlos D, Moulopoulos LA, Razis E,
Kalofonos HP, Aravantinos G, Briassoulis E et al: Dose-dense sequential chemotherapy with epirubicin and
paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study
conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol 2001, 19(8):2232-2239.
97.
Briasoulis E, Pavlidis N: Noncardiogenic pulmonary edema: an unusual and serious complication of
anticancer therapy. Oncologist 2001, 6(2):153-161.
98.
Briasoulis E, Andreopoulou E, Tolis CF, Bairaktari E, Katsaraki A, Dimopoulos MA, Fountzilas G,
Seferiadis C, Pavlidis N: G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients
treated in an adjuvant setting. Cancer 2001, 91(5):909-917.
99.
Briasoulis E, Agnantis NJ, Zagorianakou P, Kamina S, Gorezi M, Pavlidis N, Bai M: Near-absolute
expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable
outcome. Results of a clinicopathological study. J Exp Clin Cancer Res 2001, 20(3):341-344.
100. Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, Bousoulegas
A, Basdanis G, Giannoulis E, Dokmetzioglou J et al: Fluorouracil and leucovorin with or without interferon
alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study
conducted by the Hellenic Cooperative Oncology Group. Oncology 2000, 58(3):227-236.
101. Briasoulis E, Karavasilis V, Pavlidis N: Successful rechallenge with taxanes following prophylactic
ketotifen in patients who had developed severe hypersensitivity reactions. Ann Oncol 2000, 11(7):899.
102. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D,
Christodoulou C, Kosmidis P, Pavlidis N: Carboplatin plus paclitaxel in unknown primary carcinoma: a
phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000, 18(17):3101-3107.
103. Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch
G, Siamopoulos K et al: Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with
potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of
the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin
Oncol 2000, 18(20):3535-3544.
104. Briasoulis E, Froudarakis M, Milionis HJ, Peponis I, Constantopoulos S, Pavlidis N: Chemotherapyinduced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with
granulocyte colony-stimulating factor support. Respiration 2000, 67(6):680-683.
9